SOLICITATION NOTICE
66 -- Axiom Genome Wide YRI Genotyping Bundle
- Notice Date
- 8/22/2011
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HG)-2011-324-DLM
- Archive Date
- 9/15/2011
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. The solicitation number is NHLBI-CSB-(AR)-2011-324-DLM and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2005-53 (August 4, 2011). The North American Industry Classification (NAICS) Code is 334516 and the business size standard is 500. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. Background: The National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), COAC Services Branch, Office of Acquisition (OA), on behalf of the National Human Genome Research Institute (NHGRI) intends to award a firm fixed price purchase order. The National Institute of Health (NIH) is the nation's leading medical research agency and the primary Federal agency conducting, supporting and making medical discoveries that improve people's health and save lives. The mission of the Center for Research on Genomics and Global Health (CRGGH), National Human Genome Research Institute (NHGRI), National Institute of Health (NIH) is to advance research into the role of culture, lifestyle, genetics and genomics in disease etiology, differential susceptibility to disease and variable drug response at the individual and population levels. As part of this mission, the center has been collecting and analyzing samples from different parts of the world such as Africa, China and the United States to study the genetics of complex and common diseases in different populations. CRGGH's lab has ongoing large-scale genetic epidemiology studies of type 2 diabetes (T2D) in Africans. The Africa America Diabetes Mellitus (AADM) Study, as part of these studies his lab has accumulated over 2,000 DNA samples from his international collaborators in Africa to conducted genomic studies into the genetic basis of T2D with the ultimate of informing the health disparity observed in African Americans compared to their European counterparts. The purpose of the Africa America Diabetes Mellitus (AADM) study is to identify genetic variants associated with T2D and related traits in African populations through an international collaboration between African and US investigators. We chose to study T2D in African populations, where diabetes is less common than in the US, reasoning that in an environment where calories are less abundant, incidence cases of T2D might carry a proportionately greater genetic component providing a novel and highly productive subject population for genetic and epidemiological studies of T2D. Product: 1. Axiom Genome Wide YRI Genotyping Bundle, Item Number: 901788, Quantity: Nineteen (19) Each. (Must be compatible with Affymetrix GeneTitan MC Instrument). 2. Samples Genotyped on the Axiom YRI Panel, Quantity: 1,824 Samples. The Axiom Genome Wide YRI Genotyping Bundle will be used for the following : • Genotype 1200 cases of T2D and 624 controls enrolled in the Africa America Diabetes Mellitus (AADM) study using the newly design and optimized for African populations. • Genotyping of the 1,824 subjects will be conducted in the lab of The Center for Applied Genomics, Children's Hospital of Philadelphia (CHOP) using the Affymetrix YRI Axiom panel. • Conduct a genome-wide association study (GWAS) of T2D and related traits on completed genotypes adjusting for important covariates including age, sex and BMI. The AxiomTM Genome-Wide YRI Genotyping Bundle is composed of Axiom Genome-Wide YRI Array plates, Axiom 2.0 Reagent Kits and GeneTitan.® The AxiomTM Genome-Wide YRI Array Set: includes arrays, reagents, and analysis software, is part of the AxiomTM Genotyping Solution. This innovative technology for genotyping studies includes predesigned and customized array plates with validated genomic content from the AxiomTM Genomic Database of 11M validated SNPs, as well as complete reagent kits, data analysis tools, and a fully automated workflow utilizing the GeneTitan® Multi-Channel (MC) Instrument. Axiom Genome-Wide Arrays are a family of predesigned, population-optimized panels that offer optimal coverage for genome-wide association, replication, and candidate gene association studies. 1. Highest Genetic Coverage of the Yoruba Genome: a. The only commercially available genotyping array set that offers ~90% genome-wide coverage in the Yoruba genome. b. The only genotyping array set optimized to tag YRI haplotypes, including singletons. c. The only array set that offers >89.0% coverage of rare variantsin the YRI genome. d. The only array set that simultaneously offers >86% coverage in the YRI genome in all major biological categories, including cardiovascular genes, drug etabolism genes, major histocompatibilty complex (MHC), inflammatory/immunity pathway, Sanger Cancer Census and the NHGRI Catalog of Published Genome-Wide Associations. e. The only commercially available genotyping array set that offer consistent coverage across all 21 autosomal chromosomes. 2. The AxiomTM Genome-Wide YRI Array Set provides the highest genetic coverage of admixed African American genome: a. The only commercially available array set that offers ~87% genome-wide coverage of an African American genome (ASW), an admixed population based on western African and European ancestry. 3. The only YRI optimized array set that is build on the most complete YRI genome "build": a. that is constructed from HapMap, 1000 Genomes (all 3 pilot projects) and dbSNP; and b. the only commercially available array set with genetic content discovered in the Southern African Genomes Project. 4. The only commercially available array set designed with biologically and analytically validated YRI variants from the AxiomTM Genomic Database. a. The only array set validated against 630 HapMap samples, including the following: o 180 YRI HapMap samples; o 90 ASW HapMap samples; o 90 MKK HapMap samples; o 90 LWK HapMap samples; o 90 CEU HapMap samples; and o 90 JPT + CHB HapMap samples. FAR Provisions apply to this acquisition are: 1) FAR Clause 52.212-1 Instructions to Offerors Commercial Items (JUN 2008) ; 2) As stated in FAR Clause 52.212-2 (a), the Government will award a contract resulting from this solicitation to the responsible Offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered; 3) FAR Clause 52.212-4, Contract Terms and Conditions Required To Implement Statues or Executive Orders Commercial Items, Contract Terms and Conditions Commercial Items; and 4) FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items Deviation for Simplified Acquisitions. The Offeror must include in their quotation the hourly rate, unit price, total cost per year, the price list, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. Note: In order to receive an award, offerors must have a valid registration in the Central Contractor Registration (CCR) www.ccr.gov and Online Representations and Certifications Application (ORCA) www.bpn.gov. The clauses are available in full text at http://www.arnet.gov/far. Interested parties capable of furnishing the Government with the item specified in this synopsis should submit their quotation to the below address. Quotations will be due by August 31, 2011, 7:30 a.m., Eastern Standard Time. The quotation must reference Solicitation number NHLBI-CSB-(HG)-2011-324-DLM. All responsible sources may submit a quotation, which if timely received, shall be considered by the agency. Quotations must be submitted in writing to the National Heart, Lung, and Blood Institute, COAC Services Branch, Office of Acquisitions, 6701 Rockledge Blvd., Room 6149, Bethesda, Maryland 20892, Attention: Dorothy Maxwell. Responses may be submitted electronically to maxwelld@mail.nih.gov. Responses will only be accepted if dated and signed by an authorized company representative.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HG)-2011-324-DLM/listing.html)
- Place of Performance
- Address: NIH/Children's Hospital, Philadelphia, Pennsylvania, United States
- Record
- SN02544485-W 20110824/110822235642-8217717185937584ea81ab84b35d7408 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |